PureTech Health PLC 2025 AR2
The report highlights PureTech Health plc's strategic progress and sustainability achievements for the fiscal year 2025. The company advanced key clinical programs, including preparing Celea's deupirfenidone for Phase 3 trials and completing Gallop's LYT-200 Phase 1b study. PureTech maintained strong board diversity with 50 percent female representation and continued to align its operations with the UN Sustainable Development Goals. Environmentally, the company reduced energy consumption at its Boston headquarters by 14 percent and greenhouse gas emissions by 66 percent compared to the 2030 Challenge baseline.
Company: PureTech Health PLC
Sector: Professional & technical services
Country: United States
Year: 2025
Type: AR2
Pages: 228
Back to company
PureTech Health PLC
Annual Report And Accounts
The report highlights PureTech Health plc's strategic progress and sustainability achievements for the fiscal year 2025. The company advanced key clinical programs, including preparing Celea's deupirfenidone for Phase 3 trials and completing Gallop's LYT-200 Phase 1b study. PureTech maintained strong board diversity with 50 percent female representation and continued to align its operations with the UN Sustainable Development Goals. Environmentally, the company reduced energy consumption at its Boston headquarters by 14 percent and greenhouse gas emissions by 66 percent compared to the 2030 Challenge baseline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees